NEW YORK, Sept. 17 (GenomeWeb News) - 454 has extended a one-year license to now include exclusive rights to synthesizing technologies owned by Biotage, the company said today.

New Haven, Conn.-based 454 has obtains the rights to sequencing by synthesis and pyrophosphate-based sequencing for whole genome and other high density and high-throughput applications.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.